Print

Epigenomics AG Provides Update on Progress with US Product Development for Epi proColon  
1/13/2011 9:04:45 AM

(BUSINESS WIRE)--Epigenomics AG (Frankfurt Prime Standard: ECX), the cancer molecular diagnostic company, today announced that it has concluded the feasibility phase in the development of an improved product concept for Epi proColon, the Company’s DNA methylation-based blood test for assistance in the detection of individuals with colorectal cancer. This improved product concept is being developed for the US market and as a second generation product for the European and other markets. At the same time, the FDA has set a date in February for a Pre-IDE meeting to discuss with Epigenomics the product concept, its intended use and the clinical data required to support an application for marketing of the product in the US.
//-->